Micropapillary Carcinoma of the Bladder: Recent Advances
The 2016 WHO classification of tumors of the urothelial tract recently revised the classification of invasive urothelial carcinoma to include nested, microcystic, micropapillary, plasmacytoid, sarcomatoid, giant cell, and poorly differentiated variants, among others. In particular, invasive micropap...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Asian Medical Press Ltd.(H.K.)
2019-07-01
|
| Series: | Annals of Urologic Oncology |
| Subjects: | |
| Online Access: | http://auo.asmepress.com/articles/1032948_auo20190702.html |
| _version_ | 1811331123221889024 |
|---|---|
| author | Jim Hsu Jae Y. Ro |
| author_facet | Jim Hsu Jae Y. Ro |
| author_sort | Jim Hsu |
| collection | DOAJ |
| description | The 2016 WHO classification of tumors of the urothelial tract recently revised the classification of invasive urothelial carcinoma to include nested, microcystic, micropapillary, plasmacytoid, sarcomatoid, giant cell, and poorly differentiated variants, among others. In particular, invasive micropapillary carcinoma (IMPC) is now recognized as a distinct entity with aggressive features, including higher-stage disease, invasive features, and poorer response to intravesical chemotherapy. In this review, we highlight recent studies that further characterize the histopathology, immunohistochemistry, molecular mechanisms, and clinical implications of a diagnosis of IMPC. Because the correct morphologic diagnosis of IMPC is critical in terms of clinical management, we explore the diagnostic criteria of IMPC and differential diagnosis of urothelial IMPC from non-urothelial sites, highlighting studies that examine both traditional urothelial immunohistochemical markers as well as novel markers. We highlight recent advances in the molecular sub-categorization of IMPC, and review the differences compared to other forms of urothelial carcinoma. Optimal management of patients with IMPC is still unclear, although early cystectomy, regardless of pathologic stages, is recommended. We also highlight several studies that address the clinical challenges as well as current treatment protocols for IMPC. |
| first_indexed | 2024-04-13T16:14:23Z |
| format | Article |
| id | doaj.art-d7ab2067d72945b8bbe30f86e48bf2aa |
| institution | Directory Open Access Journal |
| issn | 2617-7765 2617-7773 |
| language | English |
| last_indexed | 2024-04-13T16:14:23Z |
| publishDate | 2019-07-01 |
| publisher | Asian Medical Press Ltd.(H.K.) |
| record_format | Article |
| series | Annals of Urologic Oncology |
| spelling | doaj.art-d7ab2067d72945b8bbe30f86e48bf2aa2022-12-22T02:40:07ZengAsian Medical Press Ltd.(H.K.)Annals of Urologic Oncology2617-77652617-77732019-07-0110.32948/auo.2019.07.01Micropapillary Carcinoma of the Bladder: Recent AdvancesJim Hsu0Jae Y. Ro1Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, 77030, USA.Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, 77030, USA/Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, 10065, USA.The 2016 WHO classification of tumors of the urothelial tract recently revised the classification of invasive urothelial carcinoma to include nested, microcystic, micropapillary, plasmacytoid, sarcomatoid, giant cell, and poorly differentiated variants, among others. In particular, invasive micropapillary carcinoma (IMPC) is now recognized as a distinct entity with aggressive features, including higher-stage disease, invasive features, and poorer response to intravesical chemotherapy. In this review, we highlight recent studies that further characterize the histopathology, immunohistochemistry, molecular mechanisms, and clinical implications of a diagnosis of IMPC. Because the correct morphologic diagnosis of IMPC is critical in terms of clinical management, we explore the diagnostic criteria of IMPC and differential diagnosis of urothelial IMPC from non-urothelial sites, highlighting studies that examine both traditional urothelial immunohistochemical markers as well as novel markers. We highlight recent advances in the molecular sub-categorization of IMPC, and review the differences compared to other forms of urothelial carcinoma. Optimal management of patients with IMPC is still unclear, although early cystectomy, regardless of pathologic stages, is recommended. We also highlight several studies that address the clinical challenges as well as current treatment protocols for IMPC.http://auo.asmepress.com/articles/1032948_auo20190702.htmlurothelial carcinomaurinary bladdermicropapillary carcinomaimmunohistochemistry |
| spellingShingle | Jim Hsu Jae Y. Ro Micropapillary Carcinoma of the Bladder: Recent Advances Annals of Urologic Oncology urothelial carcinoma urinary bladder micropapillary carcinoma immunohistochemistry |
| title | Micropapillary Carcinoma of the Bladder: Recent Advances |
| title_full | Micropapillary Carcinoma of the Bladder: Recent Advances |
| title_fullStr | Micropapillary Carcinoma of the Bladder: Recent Advances |
| title_full_unstemmed | Micropapillary Carcinoma of the Bladder: Recent Advances |
| title_short | Micropapillary Carcinoma of the Bladder: Recent Advances |
| title_sort | micropapillary carcinoma of the bladder recent advances |
| topic | urothelial carcinoma urinary bladder micropapillary carcinoma immunohistochemistry |
| url | http://auo.asmepress.com/articles/1032948_auo20190702.html |
| work_keys_str_mv | AT jimhsu micropapillarycarcinomaofthebladderrecentadvances AT jaeyro micropapillarycarcinomaofthebladderrecentadvances |